Effect of Celiprolol on Prevention of Cardiovascular Events in Vascular Ehlers-Danlos Syndrome

[1]  H. Dietz.  TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. , 2010, The Journal of clinical investigation.

[2]  L. Rénia,et al.  TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. , 2010, The Journal of clinical investigation.

[3]  H. Dietz,et al.  Abstract 5095: The Role of Circulating Transforming Growth Factor-{beta} in Vascular Ehlers-Danlos Syndrome: Implications for Drug Therapy , 2009 .

[4]  H. Dietz,et al.  Circulating Transforming Growth Factor-&bgr; in Marfan Syndrome , 2009, Circulation.

[5]  J. Tarlton,et al.  The relationship between cytokine concentrations and wound healing in chronic venous ulceration. , 2008, Journal of vascular surgery.

[6]  A. Dart,et al.  Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. , 2007, JAMA.

[7]  A. De Paepe,et al.  Three arginine to cysteine substitutions in the pro‐alpha (I)‐collagen chain cause Ehlers‐Danlos syndrome with a propensity to arterial rupture in early adulthood , 2007, Human mutation.

[8]  P. Byers,et al.  Aneurysm syndromes caused by mutations in the TGF-beta receptor. , 2006, The New England journal of medicine.

[9]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[10]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[11]  A. Yamane,et al.  Transforming growth factor βs are upregulated in the rat masseter muscle hypertrophied by clenbuterol, a β2 adrenergic agonist , 2006 .

[12]  Jean-PierreBecquemin,et al.  Overexpression of Transforming Growth Factor-β1 Stabilizes Already-Formed Aortic Aneurysms , 2005 .

[13]  P. Desgranges,et al.  Overexpression of Transforming Growth Factor-&bgr;1 Stabilizes Already-Formed Aortic Aneurysms: A First Approach to Induction of Functional Healing by Endovascular Gene Therapy , 2005, Circulation.

[14]  Stéphane Laurent,et al.  Increased Carotid Wall Stress in Vascular Ehlers-Danlos Syndrome , 2004, Circulation.

[15]  S. Rosenkranz,et al.  Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1 , 2002 .

[16]  C. Redmond,et al.  Biostatistics in Clinical Trials , 2002 .

[17]  B. Williams,et al.  The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation. , 2002, Journal of hypertension.

[18]  P. Byers,et al.  Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. , 2001, American journal of human genetics.

[19]  S. Laurent,et al.  Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. , 2000, Circulation.

[20]  P. Byers,et al.  Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. , 2000, The New England journal of medicine.

[21]  P. Boutouyrie,et al.  Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. , 1999, Circulation.

[22]  O. Brodde,et al.  Cardiac effects of β-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans : β1- and/or β2-adrenoceptor mediated? , 1999 .

[23]  P. Beighton,et al.  Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). , 1998, American journal of medical genetics.

[24]  P. Beighton,et al.  Ehlers‐Danlos syndromes: Revised nosology, Villefranche, 1997 , 1998 .

[25]  R. Jaenisch,et al.  Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Dowton,et al.  Respiratory complications of Ehlers‐Danlos syndrome type IV , 1996, Clinical Genetics.

[27]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[28]  F. Messerli,et al.  Hemodynamic effects of celiprolol in essential hypertension. , 1991, The American journal of cardiology.

[29]  M. Eghbali,et al.  Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. , 1991, Circulation research.

[30]  C. Wooley,et al.  The Marfan syndrome: abnormal aortic elastic properties. , 1991, Journal of the American College of Cardiology.

[31]  R. Gitzelmann,et al.  Ehlers-Danlos syndrome type IV: a multi-exon deletion in one of the two COL3A1 alleles affecting structure, stability, and processing of type III procollagen. , 1988, The Journal of biological chemistry.

[32]  J. Rosenbloom,et al.  Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. , 1987, The Biochemical journal.

[33]  S. Jimenez,et al.  Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-beta. , 1986, Biochemical and biophysical research communications.

[34]  R. Vukovich,et al.  Effect of Celiprolol, a New Beta1‐Alpha2 Blocker, on the Cardiovascular Response to Exercise , 1986, Journal of clinical pharmacology.

[35]  F. Caruso,et al.  Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. , 1985, British journal of clinical practice. Supplement.

[36]  M. Watkins.  TGF-β activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II–infused mice , 2010 .

[37]  G. Gurtner.  Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies , 2010 .

[38]  J. Stockman,et al.  Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2010 .

[39]  A. Yamane,et al.  Transforming growth factor betas are upregulated in the rat masseter muscle hypertrophied by clenbuterol, a beta2 adrenergic agonist. , 2006, British journal of pharmacology.

[40]  U. Fuhr,et al.  Effect of pretreatment with the selective β1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and β-adrenoceptor subtype specific occupancy of celiprolol in healthy man , 2004, European Journal of Clinical Pharmacology.

[41]  S. Rosenkranz,et al.  Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). , 2002, American journal of physiology. Heart and circulatory physiology.

[42]  O. Brodde,et al.  Cardiac effects of beta-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans: beta1- and/or beta2-adrenoceptor mediated? , 1999, Journal of cardiovascular pharmacology.